Clinical trials: Co-Infection HIV-HCV
Liver Cirrhosis, Hepatocellular Carcinoma
Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients
Prospective multicenter cohort recruiting consecutive patients from 7 hospitals in Andalusia, southern Spain, according to following criteria: 1) HIV infection, 2) Chronic active HCV infection, 3) Older than 18 years, 4) New…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, HIV, HCV Coinfection
- Trial name
- NCT02693847
- Where
- 8 sites in Spain
- Volunteers
- 446 people
- Sponsor
- Hospital Universitario de Valme
Hepatitis C, HIV Infections
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha…
- Conditions
- Hepatitis C, HIV Infections, COINFECTION
- Trial name
- BOC-HIV (NCT01718301)
- Testing
- boceprevir, Ribavirin, Peginterferon alfa-2a
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Anna Cruceta
HIV
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
The purpose of the study is to explore the treatment of patients with acute hepatitis C infection (infection acquired within the last 6 months) who are also infected with human immunodeficiency virus (HIV).
- Trial name
- CHAT (NCT02006745)
- Testing
- Ribavirin, Telaprevir
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St Stephens Aids Trust
Chronic Hepatitis C
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients
To compare the sustained virological response (SVR = ribonucleic acid (RNA) - hepatitis C virus (HCV) undetectable at week 24 before end the treatment) in chronic hepatitis C patients genotype 1-4 co-infected with HIV-HCV…
- Trial name
- PERICO (NCT00526448)
- Testing
- ribavirin, Peginterferon alfa-2a, epoetin beta
- Where
- 40 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Hospital Carlos III, Madrid
HIV, Hepatitis C
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
This study will evaluate the effectiveness of pioglitazone in reducing liver fat content in patients with HIV and hepatitis C virus (HCV) infections.
- Conditions
- HIV, Hepatitis C, Liver Disease, Fatty Liver
- Trial name
- NCT00742326
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Kaletra Monotherapy in HIV/HCV Co-infected Subjects
The study has been designed to test the hypothesis that in patients co-infected with HIV and HCV who exhibit maximal virologic suppression on a double class antiretroviral (ARV) regimen, including two Nucleoside Reverse…
- Trial name
- NCT00508222
- Testing
- Kaletra Tablets
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Ottawa Hospital Research Institute
Hepatitis C, Acute
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or…
- Trial name
- TARGET3D (NCT02634008)
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Where
- 11 sites in Australia, New Zealand and 1 more
- Volunteers
- 83 people
- Sponsor
- Kirby Institute
Hepatitis C Infection, HIV Infection
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.
- Trial name
- NCT02220868
- Testing
- Sofosbuvir, Ribavirin, and Stribild
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Saint Michael's Medical Center
Hepatitis C, HIV
Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia
Data on the progression of liver fibrosis in patients co-infected with HIV taking effective suppressive antiretroviral therapy with no fibrosis or mild-to-moderate fibrosis at baseline are scarce.
- Trial name
- HCV-Monitoring (NCT02628691)
- Testing
- Liver fibrosis progression
- Where
- Cambodia
- Volunteers
- 70 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections, Hepatitis C
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
The proposed studies will examine the extent of pharmacokinetic and pharmacodynamic interactions between alcohol and various antiretroviral therapies in those with HIV/AIDS, HIV/HCV co-infection, mild HCV and healthy subjects.
- Trial name
- NCT00879047
- Testing
- Alcohol
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
- Trial name
- NCT00141284
- Testing
- nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Pfizer
Hepatitis C, Chronic
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up…
- Trial name
- NCT02761629
- Testing
- Peg-Interferon Alpha-2A, Ribavirin
- Where
- 17 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
HIV Infection, HCV Coinfection
Education vs Education Plus Intervention in HIV/HCV Diagnosis (DRIVE 03)
Objectives: A targeted HIV testing strategy (TTS) through an HIV risk of exposure and indicator conditions (RE\&IC) questionnaire resulted in same rate of new HIV infection diagnosis (NHID), coverage and even reduced costs…
- Trial name
- DRIVE (NCT03145753)
- Testing
- HIV/HCV Education plus Testing, HIV/HCV Education
- Where
- 2 sites in Spain
- Volunteers
- 7,989 people, healthy volunteers welcome
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Coinfection
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
This study will evaluate the effect of ledipasvir/sofosbuvir (LDV/SOF) treatment on the pharmacokinetics (PK) and renal safety of tenofovir in the form of tenofovir alafenamide (TAF).
- Trial name
- NCT03126370
- Testing
- TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Hepatitis C, Liver Cirrhosis
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with human immunodeficiency virus-hepatitis C virus…
- Conditions
- Hepatitis C, Liver Cirrhosis, HIV Infections
- Trial name
- NCT00381017
- Testing
- Peg interferon alpha-2b
- Sponsor
- Merck Sharp & Dohme LLC
HIV/HCV Coinfection
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV).
- Trial name
- NCT02762383
- Testing
- Peginterferon Alfa-2
- Where
- 10 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
HIV, HIV Infections
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression.
- Trial name
- NCT00358696
- Testing
- tenofovir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Hepatitis C, HIV
Eliminating Hepatitis C Virus
Initially, HCV Informatics (C-IT) will be used to filter the EMR data of the one million people who receive care at Mount Sinai and identify candidates for HCV testing (baby boomers, patients with HIV infection) and candidates…
- Conditions
- Hepatitis C, HIV, Type2 Diabetes
- Trial name
- NCT03401697
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatitis C, Chronic, HIV
Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Response-guided triple-therapy with boceprevir (BOC) in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) is the current standard of care for HIV-negative patients infected with hepatitis C genotype (HCV-GT) 1.
- Trial name
- HIVCOBOC-RGT (NCT01925183)
- Testing
- Pegylated interferon alpha-2a, Ribavirin, Boceprevir
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Markus Peck-Radosavljevic